New Agents Designed to Fight EBV+ Cancers.
Researchers report using structure-based design to create small molecules capable of preventing the viral protein Epstein-Barr Nuclear Antigen 1 from binding to DNA, thus blocking viral replication. The molecules inhibited the growth of tumors in cell lines and in patient-derived xenografts of Epstein-Barr virus-positive cancers.